Prof. Bo Lei 雷博
Chief Physician, Professor
Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Minimally invasive and endoscopic surgery for benign breast tumors and breast cancer, including nipple-sparing mastectomy, oncoplastic reconstruction, and breast-conserving therapy. Manages systemic treatments such as neoadjuvant and adjuvant chemotherapy, endocrine therapy, and targeted therapy.
Dr. Lei is a Chief Physician, Professor, and Master’s Supervisor. Dr. Lei holds a medical doctorate and completed postdoctoral training.
Professional roles
- Member, Tumor Cardiology Expert Committee, Geriatric Oncology Branch, Chinese Society of Gerontology and Geriatrics
- Member, Breast Cancer Professional Committee, Heilongjiang Anti-Cancer Association
- Vice Chair, Breast Disease Branch, Heilongjiang Association of Integrative Medicine
- Vice Chair, Breast Disease Branch, Heilongjiang Chronic Disease Management Association
Name order: in Chinese the family name comes first (Lei Bo). Papers usually list the name as Bo Lei or Lei B.
Selected publications
15 papers on PubMed matched by name and affiliation; 6 as first or senior author since 2016. Most recent first- or senior-author papers:
- Breast, 2026 (senior author): Oncotype DX-guided vs physician-directed chemotherapy and survival in HR+/HER2- breast cancer. PubMed 42659874
- Cytokine Growth Factor Rev, 2023 (senior author): Exosomes-regulated lipid metabolism in tumorigenesis and cancer progression. PubMed 37291031
- J Am Heart Assoc, 2021 (first author): Exosomal Micro-RNA-96 Derived From Bone Marrow Mesenchymal Stem Cells Inhibits Doxorubicin-Induced Myocardial Toxicity by Inhibiting the Rac1/Nuclear Factor-κB Signaling Pathway. PubMed 34459233
- J Exp Clin Cancer Res, 2020 (first author): miR-615-3p promotes the epithelial-mesenchymal transition and metastasis of breast cancer by targeting PICK1/TGFBRI axis. PubMed 32336285
- Tumour Biol, 2016 (first author): Transcriptome sequencing of HER2-positive breast cancer stem cells identifies potential prognostic marker. PubMed 27629143
- Tumour Biol, 2016 (first author): Long non-coding RNA MVIH is associated with poor prognosis and malignant biological behavior in breast cancer. PubMed 26555546
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion